• Prescription drug spending is estimated to have accounted for 10.1% of

the $3.3 trillion spent on national healthcare last year.

• While specialty drug spending represents approximately 25%-30% of

the total cost of the pharmacy benefit, it is predicted that specialty drug

spend will more than quadruple by 2020, accounting for the majority of

an employers’ total pharmacy spend.

• The pharmaceutical industry will continue to have an aggressive push

toward the development of new specialty drugs, especially in the

categories of oncology, hepatitis C, and autoimmune diseases.

• U.S. oncology drug spending reached $44.1 billion in 2016, a rise of

$20.7 billion since 2011, while treatments for autoimmune diseases,

such as rheumatoid arthritis rose nearly 29%.

Our pharmacy analysis results in:

• Detailed pharmacy pricing terms comparison

• Executive summary cost comparison

• Plan design and claims distribution summary

• Utilization and clinical program savings

• Network savings opportunities

• Formulary disruption summary

Ironwood's pharmacy practice has saved clients an average of 15-25% of their annual pharmacy spend without ANY changes to the plan design, and in some cases, without changing PBM's. This savings is a year over years savings.

Pharmacy Solutions